Dr. Ross is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 W Magnolia Ave
Fort Worth, TX 76104Phone+1 817-759-7000Fax+1 817-759-7027
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020- University of Texas Health Science Center at HoustonChief Residency, Internal Medicine, 2016 - 2017
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2013 - 2016
Virginia Commonwealth University School of MedicineClass of 2013
Texas Christian UniversityBBA, Accounting, Finance, Chemistry, Cum Laude, 2004 - 2009
Certifications & Licensure
TX State Medical License 2014 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Management of DOAC-related bleeding in cancer patients: a single center-case series.Sophia Lee, Jeremy A Ross, Ali Zalpour, Jason T Henry, Cristhiam M Rojas Hernandez
Journal of Thrombosis and Thrombolysis. 2024-04-01 - 16 citationsLenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Recept...Andrew James Wiele, Tharakeswara K. Bathala, Andrew W. Hahn, Lianchun Xiao, Munevver Duran
The Oncologist. 2021-06-01 - 7 citationsOutcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.Jad Chahoud, Pavlos Msaouel, Jeremy A. Ross, Barrett McCormick, Tharakeswara K. Bathala
Urologic Oncology. 2021-02-01
Abstracts/Posters
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOACs) versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboemboli...Ross, J., Miller, M., Rojas Hernandez, C, International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, 4/7/2016
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOACs) versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboemboli...Jeremy A Ross, MD, Marilyn Miller, MSN-RN, FNP-C and Cristhiam M Rojas Hernandez, MD, American Society of Hematology Annual Meeting, Orlando, Florida USA, 12/5/2015
Committees
- Chair, Internal Medicine Residency Council 2015 - 2016
- Member, Memorial Hermann Resident Quality & Patient Safety Committee 2014 - 2015
Professional Memberships
- Member
- Member
- Member
- Member
- The Herb Fred Medical SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
